

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

FAMY CARE LIMITED,
Petitioner

v.

ALLERGAN, INC.
Patent Owner

Case IPR2017-00571
Patent 8,685,930

**PATENT OWNER ALLERGAN, INC.'S
MANDATORY NOTICES**

**PATENT OWNER'S MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8**

Pursuant to 37 C.F.R. § 42.8, the patent owner, Allergan, Inc. ("Patent Owner"), hereby submits the following Mandatory Notices in response to the Petition for *Inter Partes* Review of U.S. Patent No. 8,685,930.

1. Real Party-In-Interest under 37 CFR § 42.8(b)(1)

Allergan, Inc. is the Patent Owner and the Real Party-In-Interest in this proceeding.

2. Related Matters under 37 CFR § 42.8(b)(2)

The following judicial or administrative matters may affect or be affected by a decision in this proceeding: *Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., et al.*, No. 2:15-cv-01455 (D. Texas); *Allergan, Inc., v. Innopharma, Inc. and Pfizer, Inc.*, No. 2:15-cv-1504 (D. Texas); and *Allergan, Inc. v. Famy Care, Ltd.*, No. 2:16-cv-0401 (D. Texas).

The following petitions for *inter partes review* are related to U.S. Patent No. 8,685,930: IPR2015-01283 (terminated before institution), U.S. Patent Nos. 8,648,048 (IPR2015-01284, terminated before institution), 8,633,162 (IPR2015-01278, terminated before institution), 8,642,556 (IPR2015-01286, terminated before institution), 8,629,111 (and IPR2016-01232 and IPR2015-01282, terminated before institution).

The following petitions for *inter partes review* are pending for U.S. Patent No. 8,685,930 (IPR2016-01127, IPR2017-00594, IPR2017-00576), and related U.S. Patent Nos. 8,629,111 (IPR2016-01128, IPR2017-00567, IPR2017-00596, IPR2017-00578), 8,642,556 (IPR2016-01129 IPR2017-00570, IPR2017-00598, IPR2017-00579), 8,633,162 (IPR2016-01130 IPR2017-00568, IPR2017-00599, IPR2017-00583), 8,648,048 (IPR2016-01131, IPR2017-00566, IPR2017-00600, IPR2017-00585), and 9,248,191 (IPR2016-01132, IPR2017-00569, IPR2017-00601, IPR2017-00586).

The following patents and pending patent applications are related to U.S. Patent No. 8,685,930: U.S. Application No. 15/011,159, filed January 29, 2016, claims the benefit of U.S. Application No. 14/222,478 (9,248,191), which is a continuation, via U.S. Application Nos. 13/961,828 and 11/897,177, of U.S. Application No. 10/927,857.

3. Lead and Back-Up Counsel, under 37 CFR § 42.8(b)(3)

The Patent Owner designates the following lead and back-up counsel:

LEAD COUNSEL	BACK-UP COUNSEL
Dorothy P. Whelan, Reg. No. 33,814 3200 RBC Plaza 60 South Sixth Street Minneapolis, MN 55402 Tel: (612) 337-2509 Email: IPR13351-0008IP8@fr.com Fax: (612) 288-9696	Michael Kane, Reg. No. 39,722 3200 RBC Plaza 60 South Sixth Street Minneapolis, MN 55402 Tel: (612) 337-2502 Email: PTABI inbound@fr.com Fax: (612) 288-9696

4. Service Information under 37 CFR § 42.8(b)(4)(i) *et seq.*

Please address all correspondence and service to both counsel as listed above. Patent Owner consents to service by email at IPR13351-0008IP8@fr.com (ref.: Docket No. IPR13351-0008IP8).

Respectfully submitted,

Date/January 23, 2017/

/Dorothy P. Whelan/
Dorothy P. Whelan
Reg. No. 33,814

Customer Number 26191
Fish & Richardson P.C.
Telephone: (612) 337-2508
Facsimile: (612) 288-9696

